|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Neurology (M.G., L.M., P.M., L.V., R.B., A.C., H.B.C., H.I.H.), Biostatistics and Epidemiology (S.X.X., X.W.), and Pathology (M.S.F., V.M.-Y.L., J.Q.T.), and the Center for Neurodegenerative Disease Research (M.S.F., V.M.-Y.L.), University of Pennsylvania School of Medicine, Philadelphia; and University of Medicine and Dentistry of New Jersey–School of Osteopathic Medicine (D.J.L., J.Q.T.).
* To whom correspondence should be addressed. E-mail: mgrossma{at}mail.med.upenn.edu.
Background: The natural history of patients with pathologically proven frontotemporal lobar degeneration (FTLD) is important from clinical and biologic perspectives, but is not well documented quantitatively.
Methods: We examine longitudinal decline in cognitive functioning in an autopsy-proven cohort of patients with the clinical diagnosis of a FTLD spectrum disorder or FTLD pathology using a panel of neuropsychological measures. Patients are categorized according to findings at autopsy into tau-positive FTLD, tau-negative FTLD, and frontal variant-Alzheimer disease (fvAD) subgroups.
Results: Patients decline significantly over time on all neuropsychological measures. Moreover, several measures differentiate between histopathologically distinct subgroups throughout the course of the disease process. This includes a significant double dissociation involving relative difficulty on a visual constructional measure in tau-positive patients compared to relatively impaired visual confrontation naming in tau-negative patients. Longitudinal measures of FAS naming fluency and animal naming fluency also distinguish tau-positive patients and tau-negative patients with FTLD from patients with fvAD. Other measures show significant decline but do not distinguish between histopathologic groups longitudinally.
Conclusion: Our findings suggest different longitudinal patterns of cognitive decline in pathologically defined subgroups of patients. Measures consistently distinguishing between patient subgroups can be used to bolster diagnostic accuracy throughout the course of these diseases, while measures demonstrating undifferentiated longitudinal decline may serve as useful endpoints in treatment trials.
This article has been cited by other articles:
![]() |
E. D. Huey, E. N. Goveia, S. Paviol, M. Pardini, F. Krueger, G. Zamboni, M. C. Tierney, E. M. Wassermann, and J. Grafman Executive dysfunction in frontotemporal dementia and corticobasal syndrome Neurology, February 3, 2009; 72(5): 453 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Knopman, J. H. Kramer, B. F. Boeve, R. J. Caselli, N. R. Graff-Radford, M. F. Mendez, B. L. Miller, and N. Mercaldo Development of methodology for conducting clinical trials in frontotemporal lobar degeneration Brain, November 1, 2008; 131(11): 2957 - 2968. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |